Antiviral Resistance and the Future Landscape of Hepatitis C Virus Infection Therapy
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antiviral Resistance and the Future Landscape of Hepatitis C Virus Infection Therapy
Authors
Keywords
-
Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 207, Issue suppl_1, Pages S33-S39
Publisher
Oxford University Press (OUP)
Online
2013-02-07
DOI
10.1093/infdis/jis761
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 14 DUAL ORAL THERAPY WITH THE NS5A INHIBITOR DACLATASVIR (BMS-790052) AND NS3 PROTEASE INHIBITOR ASUNAPREVIR (BMS-650032) IN HCV GENOTYPE 1B-INFECTED NULL RESPONDERS OR INELIGIBLE/INTOLERANT TO PEGINTERFERON/RIBAVIRIN
- (2012) F. Suzuki et al. JOURNAL OF HEPATOLOGY
- 1 ATOMIC: 97% RVR FOR PSI-7977 + PEG/RBV × 12 WEEK REGIMEN IN HCV GT1: AN END TO RESPONSE-GUIDED THERAPY?
- (2012) K.V. Kowdlev et al. JOURNAL OF HEPATOLOGY
- 9 TMC435 IN PATIENTS INFECTED WITH HCV GENOTYPE 1 WHO HAVE FAILED PREVIOUS PEGYLATED INTERFERON/RIBAVIRIN TREATMENT: VIROLOGIC ANALYSES OF THE ASPIRE TRIAL
- (2012) O. Lenz et al. JOURNAL OF HEPATOLOGY
- 1399 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R +ABT-333 +RIBAVIRIN ACHIEVED SVR12 IN MORE THAN 90% OF TREATMENT-NAIVE HCV GENOTYPE-1-INFECTED SUBJECTS AND 47% OF PREVIOUS NON-RESPONDERS
- (2012) F. Poordad et al. JOURNAL OF HEPATOLOGY
- 1113 ELECTRON: ONCE DAILY PSI-7977 PLUS RBV IN HCV GT1/2/3
- (2012) E.J. Gane et al. JOURNAL OF HEPATOLOGY
- Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
- (2012) Anna S. Lok et al. NEW ENGLAND JOURNAL OF MEDICINE
- In VitroResistance Profile of the Hepatitis C Virus NS3 Protease Inhibitor BI 201335
- (2011) Lisette Lagacé et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations
- (2011) Robert A. Fridell et al. HEPATOLOGY
- 1221 TREATMENT OUTCOME AND RESISTANCE ANALYSIS IN HCV GENOTYPE 1 PATIENTS PREVIOUSLY EXPOSED TO TMC435 MONOTHERAPY AND RE-TREATED WITH TMC435 IN COMBINATION WITH PEGIFNα-2A/RIBAVIRIN
- (2011) O. Lenz et al. JOURNAL OF HEPATOLOGY
- 1194 SUSTAINED VIROLOGIC RESPONSE AND BOCEPREVIR RESISTANCE-ASSOCIATED VARIANTS OBSERVED IN PATIENTS INFECTED WITH HCV GENOTPYPE 1A/1B WHEN TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN
- (2011) C. Brass et al. JOURNAL OF HEPATOLOGY
- 1229 GENOTYPIC AND PHENOTYPIC CHARACTERIZATION OF NS3 VARIANTS SELECTED IN HCV-INFECTED PATIENTS TREATED WITH ABT-450
- (2011) T. Pilot-Matias et al. JOURNAL OF HEPATOLOGY
- 8 EVOLUTION OF TREATMENT-EMERGENT RESISTANT VARIANTS IN TELAPREVIR PHASE 3 CLINICAL TRIALS
- (2011) J.C. Sullivan et al. JOURNAL OF HEPATOLOGY
- Hepatitis C virus infection in USA: an estimate of true prevalence
- (2011) Eric Chak et al. LIVER INTERNATIONAL
- Boceprevir for Untreated Chronic HCV Genotype 1 Infection
- (2011) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
- (2011) Kenneth E. Sherman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Retreatment of HCV Infection
- (2011) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- (2011) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435
- (2010) O. Lenz et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
- (2010) Paul Y Kwo et al. LANCET
- Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial
- (2010) Edward J Gane et al. LANCET
- Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding
- (2010) K. P. Romano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus
- (2010) L. Rong et al. Science Translational Medicine
- Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients
- (2009) Simone Susser et al. HEPATOLOGY
- Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
- (2009) Christophe Hézode et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
- (2009) John G. McHutchison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Peptidomimetic Therapeutic Agents Targeting the Protease Enzyme of the Human Immunodeficiency Virus and Hepatitis C Virus
- (2008) Youla S. Tsantrizos ACCOUNTS OF CHEMICAL RESEARCH
- The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors
- (2008) M. F. McCown et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antiretroviral Drug Resistance Testing in Adult HIV‐1 Infection: 2008 Recommendations of an International AIDS Society–USA Panel
- (2008) Martin S. Hirsch et al. CLINICAL INFECTIOUS DISEASES
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now